IL312380A - Compounds and methods targeting interleukin-34 - Google Patents

Compounds and methods targeting interleukin-34

Info

Publication number
IL312380A
IL312380A IL312380A IL31238024A IL312380A IL 312380 A IL312380 A IL 312380A IL 312380 A IL312380 A IL 312380A IL 31238024 A IL31238024 A IL 31238024A IL 312380 A IL312380 A IL 312380A
Authority
IL
Israel
Prior art keywords
antibody
n3pg
human subject
seq
administered
Prior art date
Application number
IL312380A
Other languages
English (en)
Hebrew (he)
Inventor
Marcio Chedid
Adam S Fleisher
Megan Brittany Lannan
Albert Lo
Mark Mintun
Victor H Obungu
Sarah Elisabeth Raines
John Randall Ii Sims
Andrew Dixon Skora
Robin Elizabeth Walsh
Elizabeth Anne West
Ming Ye
Original Assignee
Lilly Co Eli
Marcio Chedid
Adam S Fleisher
Megan Brittany Lannan
Albert Lo
Mark Mintun
Victor H Obungu
Sarah Elisabeth Raines
John Randall Ii Sims
Andrew Dixon Skora
Robin Elizabeth Walsh
Elizabeth Anne West
Ming Ye
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Marcio Chedid, Adam S Fleisher, Megan Brittany Lannan, Albert Lo, Mark Mintun, Victor H Obungu, Sarah Elisabeth Raines, John Randall Ii Sims, Andrew Dixon Skora, Robin Elizabeth Walsh, Elizabeth Anne West, Ming Ye filed Critical Lilly Co Eli
Publication of IL312380A publication Critical patent/IL312380A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL312380A 2021-10-29 2022-10-27 Compounds and methods targeting interleukin-34 IL312380A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163273216P 2021-10-29 2021-10-29
PCT/US2022/078776 WO2023076995A1 (en) 2021-10-29 2022-10-27 Compounds and methods targeting interleukin-34

Publications (1)

Publication Number Publication Date
IL312380A true IL312380A (en) 2024-06-01

Family

ID=84367272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312380A IL312380A (en) 2021-10-29 2022-10-27 Compounds and methods targeting interleukin-34

Country Status (18)

Country Link
US (2) US11976114B2 (enExample)
EP (1) EP4423127A1 (enExample)
JP (3) JP7622019B2 (enExample)
KR (1) KR20240099349A (enExample)
CN (1) CN118475610A (enExample)
AR (1) AR127484A1 (enExample)
AU (1) AU2022376940A1 (enExample)
CA (1) CA3236555A1 (enExample)
CL (1) CL2024001303A1 (enExample)
CO (1) CO2024005417A2 (enExample)
CR (1) CR20240170A (enExample)
DO (1) DOP2024000076A (enExample)
EC (1) ECSP24032906A (enExample)
IL (1) IL312380A (enExample)
MX (1) MX2024005153A (enExample)
PE (1) PE20241471A1 (enExample)
TW (1) TW202336034A (enExample)
WO (1) WO2023076995A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250064417A1 (en) * 2022-02-03 2025-02-27 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338796A1 (en) 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012019061A2 (en) * 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SG10201509330XA (en) 2010-08-12 2015-12-30 Lilly Co Eli Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
BR112014018961A8 (pt) 2012-02-06 2017-07-11 Genentech Inc Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado
MA40406A (fr) 2014-07-28 2016-02-04 Nogra Pharma Ltd Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin
EP3233897B1 (en) * 2014-12-19 2021-02-17 Universite de Nantes Anti il-34 antibodies
TWI703159B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CA3091810A1 (en) 2018-03-02 2019-09-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
EP3977135A1 (en) 2019-05-31 2022-04-06 Eli Lilly And Company Compounds and methods targeting human tau
AR121898A1 (es) 2020-04-30 2022-07-20 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34

Also Published As

Publication number Publication date
CL2024001303A1 (es) 2024-08-30
AU2022376940A1 (en) 2024-05-02
CA3236555A1 (en) 2023-05-04
JP2025063187A (ja) 2025-04-15
KR20240099349A (ko) 2024-06-28
US11976114B2 (en) 2024-05-07
EP4423127A1 (en) 2024-09-04
CO2024005417A2 (es) 2024-05-30
TW202336034A (zh) 2023-09-16
AR127484A1 (es) 2024-01-31
DOP2024000076A (es) 2024-06-16
US20230279094A1 (en) 2023-09-07
JP2023067832A (ja) 2023-05-16
CR20240170A (es) 2024-05-24
US20240309082A1 (en) 2024-09-19
MX2024005153A (es) 2024-05-13
CN118475610A (zh) 2024-08-09
PE20241471A1 (es) 2024-07-17
JP2024091777A (ja) 2024-07-05
WO2023076995A1 (en) 2023-05-04
JP7622019B2 (ja) 2025-01-27
ECSP24032906A (es) 2024-05-31

Similar Documents

Publication Publication Date Title
JP2022002524A5 (enExample)
JP2018535648A5 (enExample)
FI3350218T3 (fi) Polyoomavirusta neutraloivia vasta-aineita
JP6054864B2 (ja) 抗腫瘍壊死因子αヒト化抗体
CN119487079A (zh) 一种pvrig/tigit双特异性抗体药物组合物及其用途
IL312380A (en) Compounds and methods targeting interleukin-34
CN112480259B (zh) 抗tnfr2抗体及其用途
JP2024091777A5 (enExample)
JP2025063187A5 (enExample)
JP2025168424A (ja) 急性期の視神経脊髄炎の予防又は治療剤
CN114466862A (zh) 兽用细小病毒抗体
JP7781519B2 (ja) グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
US9777067B2 (en) HER2- and VEGF-A-binding proteins with enhanced stability
JP7377185B2 (ja) 抗ヒトｔｌｒ７抗体
US11028184B2 (en) Long-acting PCSK9-specific binding protein and application thereof
US20230025707A1 (en) Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same
US20130004516A1 (en) Drug for inflammatory bowel disease
US20240166733A1 (en) A-fabp neutralizing monoclonal antibody and preparation method and use thereof
JPWO2022135467A5 (enExample)
US20250215100A1 (en) Antigen binding protein targeting cd40, and preparation therefor and use thereof
TWI887333B (zh) 失智症之預防或治療劑
US20230391890A1 (en) Therapeutic cemip antibodies
TW202417512A (zh) 含有抗tigit抗體的配製物及其使用方法
CN117982437A (zh) 一种靶向冠状病毒的抗体制剂及其应用
CN119613556A (zh) TrkA特异性结合蛋白及其制备和应用